|
|
Exchange: |
New York Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
134,770,000 |
Market
Cap: |
19.18(B) |
Last
Volume: |
366,223 |
Avg
Vol: |
1,170,540 |
52
Week Range: |
$120.62 - $144.92 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
|
S&P 500 |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 724 |
Guru Rank Value : 1.3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Quest Diagnostics provides diagnostic information services. Co. is made up of two businesses: Diagnostic Information Services, which develops and delivers diagnostic information services, providing insights that allow and enable a range of customers, including patients, clinicians, hospitals, independent delivery networks (including hospital health systems), health plans, employers, accountable care organizations and direct contract entities; and Diagnostic Solutions, which includes Co.'s risk assessment services business, which provides solutions for insurers, and Co.'s healthcare information technology businesses, which provides solutions for healthcare providers.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
1,760 |
18,097 |
18,097 |
100,860 |
Total Sell Value |
$246,400 |
$2,309,019 |
$2,309,019 |
$14,306,288 |
Total People Sold |
1 |
4 |
4 |
6 |
Total Sell Transactions |
1 |
7 |
7 |
21 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Rusckowski Stephen H |
Chairman, CEO and President |
|
2020-03-06 |
4 |
OE |
$71.17 |
$16,381,768 |
D/D |
230,178 |
456,738 |
|
- |
|
Doherty Catherine T. |
SVP, Group Exec. Clin. Fran. |
|
2020-02-27 |
4 |
AS |
$109.02 |
$86,017 |
D/D |
(789) |
68,411 |
|
6% |
|
Prevoznik Michael E |
SVP & General Counsel |
|
2020-02-27 |
4 |
AS |
$109.02 |
$75,224 |
D/D |
(690) |
40,087 |
|
6% |
|
Davis J. E. |
EVP, General Diagnostics |
|
2020-02-27 |
4 |
AS |
$109.02 |
$119,922 |
D/D |
(1,100) |
38,105 |
|
6% |
|
Doherty Catherine T. |
SVP, Group Exec. Clin. Fran. |
|
2020-02-26 |
4 |
D |
$112.90 |
$87,723 |
D/D |
(777) |
69,200 |
|
- |
|
Doherty Catherine T. |
SVP, Group Exec. Clin. Fran. |
|
2020-02-26 |
4 |
AS |
$111.09 |
$40,881 |
D/D |
(368) |
69,977 |
|
4% |
|
Prevoznik Michael E |
SVP & General Counsel |
|
2020-02-26 |
4 |
D |
$112.90 |
$75,417 |
D/D |
(668) |
40,777 |
|
- |
|
Prevoznik Michael E |
SVP & General Counsel |
|
2020-02-26 |
4 |
AS |
$111.09 |
$35,660 |
D/D |
(321) |
41,445 |
|
4% |
|
Davis J. E. |
EVP, General Diagnostics |
|
2020-02-26 |
4 |
D |
$112.90 |
$134,012 |
D/D |
(1,187) |
39,205 |
|
- |
|
Davis J. E. |
EVP, General Diagnostics |
|
2020-02-26 |
4 |
AS |
$111.09 |
$56,656 |
D/D |
(510) |
40,392 |
|
4% |
|
Guinan Mark |
Executive Vice President & CFO |
|
2020-02-26 |
4 |
D |
$112.90 |
$134,916 |
D/D |
(1,195) |
69,756 |
|
- |
|
Rusckowski Stephen H |
Chairman, CEO and President |
|
2020-02-26 |
4 |
D |
$112.90 |
$485,357 |
D/D |
(4,299) |
226,560 |
|
- |
|
Deppe Michael J |
VP, Corp. Controller & CAO |
|
2020-02-26 |
4 |
D |
$112.90 |
$11,064 |
D/D |
(98) |
24,416 |
|
- |
|
Eglinton Manner Carrie |
SVP, Advanced Diagnostics |
|
2020-02-26 |
4 |
D |
$112.90 |
$87,272 |
D/D |
(773) |
24,889 |
|
- |
|
Rusckowski Stephen H |
Chairman, CEO and President |
|
2020-02-25 |
4 |
D |
$113.34 |
$235,067 |
D/D |
(2,074) |
230,859 |
|
- |
|
Guinan Mark |
Executive Vice President & CFO |
|
2020-02-25 |
4 |
D |
$113.34 |
$64,037 |
D/D |
(565) |
70,951 |
|
- |
|
Eglinton Manner Carrie |
SVP, Advanced Diagnostics |
|
2020-02-25 |
4 |
D |
$113.34 |
$47,943 |
D/D |
(423) |
25,662 |
|
- |
|
Prevoznik Michael E |
SVP & General Counsel |
|
2020-02-25 |
4 |
D |
$113.34 |
$34,795 |
D/D |
(307) |
41,766 |
|
- |
|
Deppe Michael J |
VP, Corp. Controller & CAO |
|
2020-02-25 |
4 |
D |
$113.34 |
$5,554 |
D/D |
(49) |
24,514 |
|
- |
|
Davis J. E. |
EVP, General Diagnostics |
|
2020-02-25 |
4 |
D |
$113.34 |
$62,564 |
D/D |
(552) |
40,902 |
|
- |
|
Davis J. E. |
EVP, General Diagnostics |
|
2020-02-25 |
4 |
AS |
$112.73 |
$67,413 |
D/D |
(598) |
41,454 |
|
5% |
|
Doherty Catherine T. |
SVP, Group Exec. Clin. Fran. |
|
2020-02-25 |
4 |
D |
$113.34 |
$40,349 |
D/D |
(356) |
70,345 |
|
- |
|
Doherty Catherine T. |
SVP, Group Exec. Clin. Fran. |
|
2020-02-25 |
4 |
AS |
$112.73 |
$45,656 |
D/D |
(405) |
70,701 |
|
5% |
|
Rusckowski Stephen H |
Chairman, CEO and President |
|
2020-02-24 |
4 |
D |
$112.17 |
$269,657 |
D/D |
(2,404) |
232,933 |
|
- |
|
Guinan Mark |
Executive Vice President & CFO |
|
2020-02-24 |
4 |
D |
$112.17 |
$73,247 |
D/D |
(653) |
71,516 |
|
- |
|
1541 Records found
|
|
Page 14 of 62 |
|
|